Pfizer Inc.
PFE
NYSE
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
12/31/2023 | 10/01/2023 | 07/02/2023 | 04/02/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | -41.34% | -41.55% | -54.10% | -28.76% | 1.90% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -41.34% | -41.55% | -54.10% | -28.76% | 1.90% |
Cost of Revenue | 26.40% | -45.25% | -64.13% | -52.33% | 6.84% |
Gross Profit | -91.84% | -40.20% | -49.91% | -13.81% | -1.50% |
SG&A Expenses | 6.77% | 6.03% | 4.32% | 47.70% | 29.38% |
Depreciation & Amortization | 12.02% | 43.43% | 44.04% | 32.10% | 18.18% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 12.62% | -17.71% | -32.85% | -24.11% | 11.00% |
Operating Income | -233.94% | -70.89% | -79.14% | -35.63% | -21.19% |
Income Before Tax | -178.95% | -137.24% | -80.18% | -30.73% | 36.70% |
Income Tax Expenses | -445.65% | -370.79% | -104.52% | -38.99% | -7.63% |
Earnings from Continuing Operations | -166.68% | -127.63% | -76.31% | -29.50% | 39.78% |
Earnings from Discontinued Operations | -1,400.00% | 157.14% | -105.88% | 111.11% | 101.08% |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -12.50% | 60.00% | -83.33% | -116.67% | -500.00% |
Net Income | -167.46% | -127.67% | -76.51% | -29.51% | 47.19% |
EBIT | -233.94% | -70.89% | -79.14% | -35.63% | -21.19% |
EBITDA | -179.96% | -60.18% | -69.62% | -29.46% | -15.47% |
EPS Basic | -167.08% | -127.48% | -76.73% | -29.73% | 47.20% |
Normalized Basic EPS | -211.54% | -69.98% | -76.28% | -31.54% | -19.83% |
EPS Diluted | -169.03% | -128.01% | -76.41% | -29.10% | 47.10% |
Normalized Diluted EPS | -214.08% | -69.39% | -76.06% | -30.95% | -19.50% |
Average Basic Shares Outstanding | 0.57% | 0.70% | 0.95% | 0.30% | -0.02% |
Average Diluted Shares Outstanding | -1.67% | -1.26% | 0.02% | -0.54% | -0.43% |
Dividend Per Share | 2.50% | 2.50% | 2.50% | 2.50% | 2.56% |
Payout Ratio | -2.53% | -- | 3.39% | 0.45% | -0.30% |